# Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

> **NCT00550771** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 181 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
- **DRUG:** PLD, cyclophosphamide, trastuzumab, paclitaxel

## Key facts

- **NCT ID:** NCT00550771
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-16
- **Primary completion:** 2010-08-23
- **Final completion:** 2010-08-23
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550771, "Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00550771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*